Literature DB >> 30826985

PAX3 Promotes Proliferation of Human Glioma Cells by WNT/β-Catenin Signaling Pathways.

Xia Liang1, Zhao Dong2, Wu Bin1, Nie Dekang3, Zhu Xuhang4, Zhang Shuyuan1, Li Liwen1, Jin Kai1, Sun Caixing5.   

Abstract

The PAX3 (paired box 3) gene plays an important role in embryonic development, diseases, and cancer formation. Our preliminary studies have shown that PAX3 gene is upregulated in glioma cells, which is associated with a worse prognosis. Moreover, PAX3, by facilitating cell proliferation and invasion and inhibiting cell apoptosis, plays an oncogenic role in glioma. However, the specific molecular mechanism of PAX3 acting as an oncogene in glioma remains unclarified. In the present study, we have found that PAX3 overexpression was observed in high grade glioma and predicted a worse prognosis. PAX3 overexpression did not correlate significantly to IDH1 mutation and MGMT methylation. Moreover, the expression of PAX3 was positively correlated with that of β-catenin. In U87 glioma cells, PAX3 interacted with β-catenin, as was confirmed by CO-IP. Besides, PAX3 overexpression promoted cell proliferation and cell cycle progression, while it inhibited cell apoptosis by altering the expressions of important molecules associated with the Wnt signaling pathway, including β-catenin, Myc, VEGF, cyclinD1, MMP7, and Wnt1. In the meantime, it was also proved that PAX3 correlated to β-catenin through a negative regulatory mechanism with respect to the promotion of U87 glioma cell proliferation and cell cycle progression and inhibition of the cell apoptosis. Our experiment demonstrated the role of PAX3 in promoting glioma growth and development, possibly by interacting directly with β-catenin and regulating the Wnt signaling pathway.

Entities:  

Keywords:  Glioma; Oncogene; PAX3; Wnt; β-Catenin

Mesh:

Substances:

Year:  2019        PMID: 30826985     DOI: 10.1007/s12031-019-01283-2

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  29 in total

1.  High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  R Stupp; J-C Tonn; M Brada; G Pentheroudakis
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

Review 2.  The expression and function of PAX3 in development and disease.

Authors:  Salah Boudjadi; Bishwanath Chatterjee; Wenyue Sun; Prasantha Vemu; Frederic G Barr
Journal:  Gene       Date:  2018-05-04       Impact factor: 3.688

Review 3.  Pax genes: regulators of lineage specification and progenitor cell maintenance.

Authors:  Judith A Blake; Melanie R Ziman
Journal:  Development       Date:  2014-02       Impact factor: 6.868

4.  Downregulation of Pax3 expression correlates with acquired GFAP expression during NSC differentiation towards astrocytes.

Authors:  Yan Liu; Hui Zhu; Mei Liu; Jinfeng Du; Yuyan Qian; Yongjun Wang; Fei Ding; Xiaosong Gu
Journal:  FEBS Lett       Date:  2011-03-01       Impact factor: 4.124

Review 5.  Wnt/beta-catenin signaling in cancer stemness and malignant behavior.

Authors:  Riccardo Fodde; Thomas Brabletz
Journal:  Curr Opin Cell Biol       Date:  2007-02-16       Impact factor: 8.382

Review 6.  WNT signalling pathways as therapeutic targets in cancer.

Authors:  Jamie N Anastas; Randall T Moon
Journal:  Nat Rev Cancer       Date:  2013-01       Impact factor: 60.716

7.  Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma.

Authors:  N Galili; R J Davis; W J Fredericks; S Mukhopadhyay; F J Rauscher; B S Emanuel; G Rovera; F G Barr
Journal:  Nat Genet       Date:  1993-11       Impact factor: 38.330

8.  PAX3 is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells.

Authors:  Liang Xia; Qingfeng Huang; Dekang Nie; Jinlong Shi; Mingjie Gong; Bin Wu; Peipei Gong; Longxiang Zhao; Hao Zuo; Shaoqin Ju; Jian Chen; Wei Shi
Journal:  Brain Res       Date:  2013-05-20       Impact factor: 3.252

9.  Heterogeneous expression of Wnt/beta-catenin target genes within colorectal cancer.

Authors:  Falk Hlubek; Thomas Brabletz; Jan Budczies; Sabine Pfeiffer; Andreas Jung; Thomas Kirchner
Journal:  Int J Cancer       Date:  2007-11-01       Impact factor: 7.396

10.  SEOM clinical guidelines for anaplastic gliomas (2017).

Authors:  A Hernandez; C Balañá; M Alonso; P Perez-Segura; E Pineda; A Ramos; A R Sanchez; P Teixidor; E Verger; M Benavides
Journal:  Clin Transl Oncol       Date:  2017-10-20       Impact factor: 3.405

View more
  4 in total

1.  Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.

Authors:  Zhenzhe Li; Jixing Zhang; Hongshan Zheng; Chenlong Li; Jinsheng Xiong; Weiliang Wang; Hongbo Bao; Hua Jin; Peng Liang
Journal:  J Exp Clin Cancer Res       Date:  2019-08-28

2.  Emerging Pathogenic and Prognostic Significance of Paired Box 3 (PAX3) Protein in Adult Gliomas.

Authors:  Efthalia Angelopoulou; Yam Nath Paudel; Christina Piperi
Journal:  Transl Oncol       Date:  2019-07-25       Impact factor: 4.243

3.  miR-299-3p suppresses cell progression and induces apoptosis by downregulating PAX3 in gastric cancer.

Authors:  Zhenfen Wang; Qing Liu; Ping Huang; Guohao Cai
Journal:  Open Life Sci       Date:  2021-03-23       Impact factor: 0.938

4.  Farnesoid X receptor antagonizes Wnt/β-catenin signaling in colorectal tumorigenesis.

Authors:  Junhui Yu; Shan Li; Jing Guo; Zhengshui Xu; Jianbao Zheng; Xuejun Sun
Journal:  Cell Death Dis       Date:  2020-08-17       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.